Tocilizumab effects over proteinuria in FMF-associated amyloidosis has been analyzed in two series of 11 and 12 patients resistant to colchicine, anti–IL-1, or anti-TNF agents, in whom the previous colchicine therapy was maintained (126, 127). This evidence concerns the gene IL1B and amyloidosis.